AMLX

#2013
Amylyx Pharmaceuticals, Inc. Common Stock
16.92 USD
+2.73%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
16.92
16.92
Intervallo Annuale
3.79
17.49
Variazione giornaliera
+2.73%
Variazione Mensile
+19.24%
Variazione di 6 mesi
+15.89%
Variazione Annuale
+332.74%
Chiusura Precedente
16.47
Apertura
16.92
Bid
Ask
Minimo
16.92
High
16.92
Volume
87
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi
Trimestrale Annuale
Conto economico Bilancio Liquidità
Valore 2022202320242025 TTM

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Notizie